|
DNAJC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.55589985340043E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.77320002704118E-09 |
| Normal-vs-Stage2 |
1.183580E-03 |
| Normal-vs-Stage3 |
3.45545814184334E-12 |
| Normal-vs-Stage4 |
8.83330075751587E-11 |
| Stage1-vs-Stage2 |
2.393600E-01 |
| Stage1-vs-Stage3 |
3.790500E-04 |
| Stage1-vs-Stage4 |
5.076700E-03 |
| Stage2-vs-Stage3 |
2.280400E-03 |
| Stage2-vs-Stage4 |
2.184400E-03 |
| Stage3-vs-Stage4 |
5.804600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.99200722162641E-16 |
| Normal-vs-AfricanAmerican |
1.361580E-03 |
| Normal-vs-Asian |
4.14699996564849E-09 |
| Caucasian-vs-AfricanAmerican |
3.004000E-01 |
| Caucasian-vs-Asian |
9.153200E-01 |
| AfricanAmerican-vs-Asian |
3.593800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.40339978421866E-10 |
| Normal-vs-Female |
1.58320023757597E-10 |
| Male-vs-Female |
8.052000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.23600000012658E-07 |
| Normal-vs-Age(41-60Yrs) |
4.75079975359449E-11 |
| Normal-vs-Age(61-80Yrs) |
1.17500009721994E-10 |
| Normal-vs-Age(81-100Yrs) |
4.979500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.563990E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.039900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.462200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.862200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.790800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.574800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.62729995723777E-09 |
| Classical-VS-Follicular |
8.26950000000215E-05 |
| Classical-VS-Other |
3.493000E-01 |
| Classical-VS-Normal |
1.71684888528034E-12 |
| Tall-VS-Follicular |
3.73590047786365E-12 |
| Tall-VS-Other |
3.260200E-01 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
5.674200E-02 |
| Follicular-VS-Normal |
2.432400E-02 |
| Other-VS-Normal |
6.954600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.0356999997957E-07 |
| Normal-vs-N1 |
2.394640041814E-12 |
| N0-vs-N1 |
5.53890000000168E-05 |
|
|
